Exposure of ovalbumin during pregnancy prevents the development of allergic rhinitis in offspring through the induction of mast cell autophagy

2021 ◽  
Vol 365 ◽  
pp. 104362
Author(s):  
Hee-Yun Kim ◽  
Sun-Young Nam ◽  
Hyung-Min Kim ◽  
Hyun-Ja Jeong
Keyword(s):  
Allergic Rhinitis ◽  
Mast Cell

scholarly journals Segmental Bronchoprovocation in Allergic Rhinitis Patients Affects Mast Cell and Basophil Numbers in Nasal and Bronchial Mucosa

2001 ◽  
Vol 164 (5) ◽  
pp. 858-865 ◽  
Author(s):  
GERT-JAN BRAUNSTAHL ◽  
SHELLEY E. OVERBEEK ◽  
WYTSKE J. FOKKENS ◽  
ALEX KLEINJAN ◽  
ALAN R. McEUEN ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Mast Cell ◽  
Bronchial Mucosa

Therapeutic Advances in the Management of Allergic Rhinitis and Urticaria

1994 ◽  
Vol 111 (3P2) ◽  
pp. 364-372 ◽  
Author(s):  
Helen F. Krause
Keyword(s):  
Allergic Rhinitis ◽  
Mast Cell ◽  
Clinical Studies ◽  
Recent Literature ◽  
Late Phase ◽  
Considerable Change ◽  
Receptor Antagonists ◽  
Intranasal Medications

Therapy for patients with allergic rhinitis and urticaria has undergone considerable change in recent years because the mechanisms of these diseases have been more clearly elucidated. Both appear to have marked inflammatory components. A review of the recent literature reveals that clinical studies of both classic and new nonsedating H1-receptor antagonists, H2-receptor antagonists, a variety of intranasal medications, and mast-cell stabilizers demonstrate variable roles in the management of these diseases. Because allergic rhinitis has early-and late-phase reactions, therapy must be directed toward control of both responses. There are a number of types of urticaria; therapy for each may vary.

Mast cell stabilizers

1992 ◽  
Vol 107 (6_part_2) ◽  
pp. 841-844 ◽  
Author(s):  
Hueston C. King
Keyword(s):  
Allergic Rhinitis ◽  
Mast Cell ◽  
Cell Membrane ◽  
Nasal Mucosa ◽  
Nasal Polyps ◽  
Nasal Congestion ◽  
Correct Diagnosis ◽  
Vasomotor Rhinitis ◽  
Ige Mediated ◽  
Exercise Induced

The precise mode of action of the well-studied cromolyn sodium and the newer nedocromil sodium has not been completely elucidated. Because the drugs do not pass the cell membrane and enter the cell, they are virtually not metabolized, do not exert a systemic action, and therefore are associated with only minimal systemic toxicity. To be effective either drug must be applied topically and directly to the nasal mucosa. Proper contact with the nasal mucosa is essential for efficacy; in patients with nasal congestion and secretions, vasoconstrictors or saline lavages are indicated before cromolyn or nedocromil use. Both products are highly effective in patients who have IgE-mediated allergic rhinitis but must be administered prophylactically before exposure to an allergen to prevent development of the allergic event. Neither drug is effective in vasomotor rhinitis, exercise-induced rhinitis, or in the management of nasal polyps. Correct diagnosis is essential before therapy.

Sign in / Sign up

Export Citation Format

Share Document